Drug intelligence / Profile preview

Actinium (225Ac) rhPSMA-10.1 Injection

Development stage: Unknown
Lead developer: Blue Earth Therapeutics
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Alpha Emitters → Radiopharmaceuticals, Small Molecules
Administration: Intravenous

Overview

Actinium (225Ac) rhPSMA-10.1 Injection is an investigational alpha-emitting radiopharmaceutical developed by Blue Earth Therapeutics in collaboration with University College London (UCL). It consists of the alpha-emitting radionuclide actinium-225 (225Ac) conjugated to rhPSMA-10.1, a proprietary radiohybrid prostate-specific membrane antigen (PSMA)-targeting small molecule. The drug is designed to target PSMA, which is highly overexpressed on prostate cancer cells, and deliver high-energy, short-range alpha radiation directly to the tumor lesions. This localized radiation induces lethal double-strand DNA breaks in the cancer cells while minimizing damage to surrounding healthy tissues. It is currently being evaluated in the Phase 1/2 ACT-RESoLUTE clinical trial (NCT07414940) for the treatment of patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) whose disease has progressed following prior therapies.

Other names: 225Ac-radiohybrid-(rh)PSMA-theranostics225Ac-rh PSMA-theranostics225Ac-rhPSMAactinium (225Ac) radiohybrid prostate-specific membrane antigen-10.1actinium (225Ac) rhPSMA-10.1actinium-225 rhPSMA-10.1actinium225 rhPSMA-10.1actinium 225 rhPSMA-10.1actinium-225 rhPSMA-10.1 injectionactinium225 rhPSMA-10.1 injectionactinium 225 rhPSMA-10.1 injection

Targets

DNAPSMA (Prostate-specific membrane antigen)

Beyond the preview

Go deeper on Actinium (225Ac) rhPSMA-10.1 Injection.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Actinium (225Ac) rhPSMA-10.1 Injection.